000088536 001__ 88536 000088536 005__ 20210902121631.0 000088536 0247_ $$2doi$$a10.1186/s12902-019-0478-9 000088536 0248_ $$2sideral$$a117211 000088536 037__ $$aART-2020-117211 000088536 041__ $$aeng 000088536 100__ $$aManios, Y. 000088536 245__ $$aTwo-stage, school and community-based population screening successfully identifies individuals and families at high-risk for type 2 diabetes: The Feel4Diabetes-study 000088536 260__ $$c2020 000088536 5060_ $$aAccess copy available to the general public$$fUnrestricted 000088536 5203_ $$aBackground: The implementation of population screening and early prevention strategies targeting individuals at high-risk for type 2 diabetes (T2D) seems to be a public health priority. The current work aimed to describe the screening procedure applied in the Feel4Diabetes-study and examine its effectiveness in identifying individuals and families at high risk, primarily for T2D and secondarily for hypertension, among vulnerable populations in low to middle-income countries (LMICs) and high-income countries (HICs) across Europe. Methods: A two-stage screening procedure, using primary schools as the entry-point to the community, was applied in low socioeconomic status (SES) regions in LMICs (Bulgaria-Hungary), HICs (Belgium-Finland) and HICs under austerity measures (Greece-Spain). During the first-stage screening via the school-setting, a total of 20, 501 parents (mothers and/or fathers) of schoolchildren from 11, 396 families completed the Finnish Diabetes Risk Score (FINDRISC) questionnaire, while their children underwent anthropometric measurements in the school setting. Parents from the identified "high-risk families" (n = 4484) were invited to participate in the second-stage screening, including the measurement of fasting plasma glucose (FPG) and blood pressure (BP). In total, 3153 parents participated in the second-stage screening (mean age 41.1 ± 5.6 years, 65.8% females). Results: Among parents who attended the second-stage screening, the prevalence of prediabetes (as defined by impaired fasting glucose; FPG 100-125 mg/dl) and T2D (FPG > 126 mg/dl) was 23.2 and 3.0% respectively, and it was found to be higher in the higher FINDRISC categories. The percentage of undiagnosed T2D among the participants identified with T2D was 53.5%. The prevalence of high normal BP (systolic BP 130-139 mmHg and/or diastolic BP 85-89 mmHg) and hypertension (systolic BP = 140 mmHg and/or diastolic BP = 90 mmHg) was 14 and 18.6% respectively, which was also higher in the higher FINDRISC categories. The percentage of cases not receiving antihypertensive treatment among the participants identified with hypertension was 80.3%. Conclusion: The findings of the current study indicate that the two-stage school and community-based screening procedure followed, effectively identified high-risk individuals and families in vulnerable populations across Europe. This approach could be potentially scalable and sustainable and support initiatives for the early prevention of T2D and hypertension. 000088536 536__ $$9info:eu-repo/grantAgreement/EC/H2020/643708/EU/Developing and implementing a community-based intervention to create a more supportive social and physical environment for lifestyle changes to prevent diabetes in vulnerable families across Europe/Feel4Diabetes$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 643708-Feel4Diabetes 000088536 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000088536 590__ $$a2.763$$b2020 000088536 591__ $$aENDOCRINOLOGY & METABOLISM$$b110 / 145 = 0.759$$c2020$$dQ4$$eT3 000088536 592__ $$a0.743$$b2020 000088536 593__ $$aMedicine (miscellaneous)$$c2020$$dQ2 000088536 593__ $$aEndocrinology, Diabetes and Metabolism$$c2020$$dQ2 000088536 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000088536 700__ $$aMavrogianni, C. 000088536 700__ $$aLambrinou, C.P. 000088536 700__ $$aCardon, G. 000088536 700__ $$aLindström, J. 000088536 700__ $$aIotova, V. 000088536 700__ $$aTankova, T. 000088536 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira, F.$$uUniversidad de Zaragoza 000088536 700__ $$aKivelä, J. 000088536 700__ $$aJancsó, Z. 000088536 700__ $$aShadid, S. 000088536 700__ $$aTsochev, K. 000088536 700__ $$0(orcid)0000-0001-6650-8294$$aMateo-Gallego, R.$$uUniversidad de Zaragoza 000088536 700__ $$aRadó, S. 000088536 700__ $$aDafoulas, G. 000088536 700__ $$aMakrilakis, K. 000088536 700__ $$aAndroutsos, O. 000088536 7102_ $$11006$$2255$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Enfermería 000088536 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000088536 773__ $$g20, Suppl 1 (2020), 12 [11 pp.]$$pBMC ENDOCRINE DISORDERS$$tBMC endocrine disorders$$x1472-6823 000088536 8564_ $$s861280$$uhttps://zaguan.unizar.es/record/88536/files/texto_completo.pdf$$yVersión publicada 000088536 8564_ $$s47414$$uhttps://zaguan.unizar.es/record/88536/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000088536 909CO $$ooai:zaguan.unizar.es:88536$$particulos$$pdriver 000088536 951__ $$a2021-09-02-08:52:59 000088536 980__ $$aARTICLE